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https://doi.org/10.1016/j.jaci.2017.09.039Methods: After bronchoscopy, ribosomal internal transcribed
spacer region 1 DNA was amplified and sequenced and fungal
load determined by real-time PCR. Clinical and treatment
variables were correlated with the main species identified.
Bronchopulmonary aspergillosis (n 5 16), severe asthma with
fungal sensitization (n 5 16), severe asthma not sensitized to
fungi (n 5 9), mild asthma patients (n 5 7), and 10 healthy
control subjects were studied.
Results: The mycobiome was highly varied with severe
asthmatics carrying higher loads of fungus. Healthy individuals
had low fungal loads, mostly poorly characterizedMalasezziales.
The most common fungus in asthmatics was Aspergillus
fumigatus complex and this taxon accounted for the increased
burden of fungus in the high-level samples. Corticosteroid
treatment was significantly associated with increased fungal
load (P < .01).
Conclusions: The mycobiome is highly variable. Highest loads
of fungus are observed in severe asthmatics and the most
common fungus is Aspergillus fumigatus complex. Individuals
receiving steroid therapy had significantly higher levels of
Aspergillus and total fungus in their bronchoalveolar lavage.
(J Allergy Clin Immunol 2017;nnn:nnn-nnn.)
Key words: Lung mycobiome, Aspergillus, steroid, antifungal,
allergic bronchopulmonary aspergillosis, asthma
Fungal diseases are a serious health problem worldwide.1
A common form of fungal disease is caused by allergic reactions
to fungi that complicate existing respiratory pathology. Severe
asthma is frequently linked with fungal sensitization.2 Recog-
nized asthma endotypes include allergic bronchopulmonary
mycosis,3 which includes allergic bronchopulmonary aspergil-
losis (ABPA).4 A recently proposed phenotype of severe asthma
is severe asthma with fungal sensitization (SAFS).5 All are
serious airway diseases whose pathogenesis is only partially un-
derstood. ABPA affects between 2% and 5% of adult asthmatics
and SAFSmay account for 40% of severe asthmatics so the health
care and economic impact of fungal allergy is significant. It is
currently assumed that ABPA and SAFS are directly linked to
fungal colonization of airways and made worse by increased
fungal burden; however, existing culture-based tests are inade-
quate to determine level and composition of fungal communities
in the lungs of affected individuals.6,7
Most of themicrobiome studies performed to date have focused
on gastrointestinal tract, oral, skin, and vaginal bacterial micro-
environments.3,8,9 The data available on the lung mycobiome (re-
viewed in Tipton et al10) is limited to samples from individuals
that did not have well-characterized fungal disease.1
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2 FRACZEK ET ALAbbreviations usedABPA: Allergic bronchopulmonary aspergillosisBAL: Bronchoalveolar lavageICS: Inhaled corticosteroidITS: Ribosomal internal transcribed spacer regionOCS: Oral corticosteroidRT-PCR: Real-time PCRSA: Severe asthma without fungal sensitizationSAFS: Severe asthma with fungal sensitizationCommonly reported fungal respiratory infections in immuno-
compromised patients are caused by fungi such as Aspergillus
spp, Candida spp, Mucorales or Cryptococcus spp.1 Endemic
pathogens such as Histoplasma spp, Coccidioides spp, and Blas-
tomyces sppmay also cause diseases in otherwise healthy individ-
uals.11 Aspergillus fumigatus causes life-threatening invasive
aspergillosis, chronic pulmonary aspergillosis, Aspergillus-asso-
ciated asthma, and allergic diseases such as ABPA and
SAFS.1,12-14 ABPA is characterized by exaggerated TH2 CD4
1
allergic inflammatory response to A fumigatus allergens,15
including proteases16 in the bronchial airway of atopic asthma
and cystic fibrosis patients. Other fungi are implicated in SAFS
and allergic bronchopulmonary mycosis.3,8 However, there are
limited data describing the range of fungal species that are pre-
sent, their relative and absolute abundances, and how antimicro-
bial or corticosteroid therapies impact these microbial
communities. Corticosteroid treatment is a known risk factor
for development of invasive aspergillosis,9,17,18 but it is also a
common treatment to alleviate symptoms of asthma.19
To establish the composition of the lung mycobiome in allergic
fungal disease, we investigated the mycobiome composition in
the lungs of healthy individuals or those with ABPA, SAFS,
asthma, and severe asthma using ribosomal internal transcribed
spacer region 1 (ITS1) sequencing, real-time (RT)-PCR and
standard microbiological culture methods. Additionally we
examined whether particular treatments were associated with
altered mycobiomes in these individuals.METHODS
Sample collection and processing
Patients were identified using the exclusion and inclusion criteria defined in
the supplemental Methods (in this article’s Online Repository at www.
jacionline.org). Briefly, 64 individuals were identified with 58 agreeing to
bronchoscopy (Table I and see Table E1 in this article’s Online Repository
at www.jacionline.org). Bronchoalveolar lavage (BAL) samples were
collected using local guidelines and British Thoracic Society standard proced-
ures.20 After bronchoscopy, all collected samples were immediately placed on
ice and transferred to the laboratory for processing. The BALwas subjected to
immediate DNA extraction, then PCR, and Illumina sequencing (Illumina Inc,
San Diego, Calif). Dilution of endogenous lung fluids in the lavage medium
was estimated as described21 using a Sigma urea assay kit (Sigma Aldrich,
Gillingham, Dorset, United Kingdom [UK]).DNA extraction, PCR, and Illumina sequencing
BAL samples were processed immediately after they were obtained,
without storage, and thenDNA extraction was carried out immediately using a
cetyl triammonium bromide method previously described.22 Control samples
consisted of sterilewater or known dilution series of A fumigatus orC albicans
DNA substituted for BAL and also added to BAL before the initial sample prepand then carried through each step in the procedure before sequencing. Where
appropriate, reads associated with potential reagent contaminant fungi were
excluded from subsequent analysis.Statistics
Unless otherwise stated, statistical analysis was performed within QIIME
v1.8 (http://qiime.org) using appropriate QIIME workflows.23-25 Beta diver-
sity for fungal taxa was calculated using Bray-Curtis metrics. Confounding
variables were selected a priori and included age, weight, sex, corticosteroid
treatment, antifungal treatment, azithromycin treatment, and disease. Groups
were stratified and differences in effects were compared to assess potential
confounding. Minimum group size after stratification was 3. Alpha diversity
metrics were calculated for fungi using an Excel spreadsheet (Microsoft,
Redmond, Wash). Numbers of fungal otus (organized taxonomic units) and
diversity statistics are shown in Table E2 (in this article’s Online Repository
at www.jacionline.org). Pairwise comparison of specific species within data-
sets was assessed using t test orMann-WhitneyU test in cases where deviation
from normal distribution was observed. Statistics were adjusted for multiple
sampling usingBenjamini-Hochberg correction as appropriate. Dunn compar-
ison test and logistical regression were used to identify potential confounding
factors in comparison of multiple groups as appropriate.Analysis of mycobiome
Fungal ITS1 sequences were compared with the UNITE database using the
QIIME 1.8 closed-reference organized taxonomic unit picking workflow.Quantification of fungal burden using RT-PCR
Overall fungal burden was determined using RT-PCRwith Aspergillus 18S
specific or pan-fungal ITS1-2 region primers as previously described.7,26,27Estimation of A fumigatus complex clonality and
diversity
To estimate clonality and diversity in the sample, we arbitrarily defined
identical ITS1 sequences as clonal and ITS1 sequences differing from themost
common clonal ITS1 sequence as diverse. It is not certain that this definition
will distinguish species within the sample. Aspergillus complex sequences
were isolated from fastq files using BLAST128 with empirically defined pa-
rameters E value < E-31, match length > 95% based on both the ability of
the A fumigatus ITS query to identify A fumigatus complex sequences in the
large ITS database and comparison of resulting sequences isolated from the
fastq files with A fumigatus complex ITS sequences from ITS databases and
from the type sequences as previously defined.29 To reduce the possibility
of misassignation from sequence error, fastq files were first filtered using
TrimmomaticSE to remove end sequences with Phred 33 scores <30 and
any sequences containing 3 base windows with quality lower than Phred 30.
Where appropriate, sequences were aligned using MUSCLE30 trimmed using
ALIVIEW31 and used to make neighbor-joining trees using PhyML in Sea-
view v4.5.4.32 Open source software cited above: BLASTp (ftp://ftp.ncbi.
nlm.nih.gov/blast/executables/LATEST/), TrimmomaticSE (http://www.
usadellab.org/cms/index.php?page=trimmomatic), MUSCLE (http://www.
drive5.com/muscle), ALIVIEW (http://ormbunkar.se/aliview/), and Seaview
(http://doua.prabi.fr/software/seaview).RESULTS
Recruitment of patients to the study
This was an observational study conducted between November
2011 and November 2013 at the National Aspergillosis Centre
and the North West Severe Asthma Centre based at the Man-
chester University NHS Foundation Trust (Wythenshawe). Sixty-
four adults (31 female and 33 male) 22 to 75 years of age were
enrolled. All current or previous smokers had <10 pack years. No
TABLE I. Patient and healthy control subject demographics
ABPA
(n 5 16)
SAFS
(n 5 16) SA (n 5 9)
Mild asthma
(n 5 7)
Normal healthy
control
(n 5 10)
P value
(ANOVA)
Characteristic
Age (y), median (range) 60 (25-75) 51.5 (30-68) 49 (19-65) 24 (22-62) 29 (22-58) .02
Male, n (%) 11 (68.7) 5 (37.5) 4 (44.4) 6 (85.7) 5 (50) .463
BMI (kg/m2), mean 6 SD 27.8 6 4.9 27.2 6 5.3 29.1 6 6.5 26.6 6 3.81 23.3 6 7.4 .845
FEV1%, mean 6 SD 64.5 6 22.2 72.8 6 20.9 58.1 6 16.9 95.5 6 12 98 6 12.9 <.001
Duration of asthma (y), mean 6 SD 42.8 6 18.8 40.6 6 17.2 31.9 6 17.5 22 6 15.6 0 .08
Bronchiectasis, n (%) 16 (100) 12 (81.3) 6 (66.7) 0 0 <.001
Obesity, n (%) 3 (20) 3 (18.7) 3 (33.3) 0 2 (20) <.582
Atopy, n (%) 11 (68.8) 12 (75) 4 (44.4) 1 (14.3) 0 <.001
Rhinitis/sinusitis, n (%) 11 (68.8) 10 (62.5) 3 (33.3) 1 (14.3) 0 .002
Nasal polyps, n (%) 5 (31.3) 6 (37.5) 2 (22.2) 0 0 .102
Total IgE (kU/L), median (range) 1025 (210-9300) 205 (53.9-680) 49.2 (14-500) 96.3 (30-580) 49.6 (7.6-660) <.001
Blood eosinophils, median (range) 0.180 (0.2-1.1) 0.38 (0.1-0.63) 0.22 (0.1-0.27) 0.04 (0-0.08) 0.15 (0.11-0.24) .111
Antifungal therapy
Current, n (%) 7 (43.8) 10 (62.5) 0 0 0 <.001
Previous, n (%) 5 (31.3) 2 (12.3) 0 0 0 <.001
Never, n (%) 4 (25) 4 (25) 9 (100) 7 (100) 10 (100) .97
Azithromycin, n (%) 6 (37.5) 7 (43.8) 6 (66.7) 0 0 .007
Oral corticosteroids, n (%) 10 (62.5) 10 (62.5) 9 (100) 0 0 <.001
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extraction was unsuccessful in 1. Therefore, 58 patients were
included in this study: ABPA, n 5 16; SAFS, n 5 16; severe
asthma without fungal sensitization (SA), n 5 9; mild asthma,
n5 7; and healthy control subjects, n5 10 (Table I and Table E2).
ABPA, SAFS, and SA patients were recruited from a cohort of pa-
tients attending the above clinics. Mild asthmatic and healthy
control subjects were recruited from among members of staff,
general public, and students from the University of Manchester.
No individual in the study had cystic fibrosis. All patients gave
written informed consent to participate in the study, which was
approved by the local Research Ethics Committee (REC refer-
ence no 11/NW/0175).Mycobiome composition of BAL samples
Results fromQIIME closed reference BLASTworkflows using
ITS1 overlapped sequences are shown in Fig 1, A-C. A fumigatus
complex is predominant in lung samples. The load of fungus was
estimated using RT-PCR and correlates closely with read count
from the rawQIIME analysis (Fig 1, A, and Fig E1 in this article’s
Online Repository at www.jacionline.org). Loads are very vari-
able across samples (Fig 1, A and B). Healthy individuals all
have low fungal burden and are characterized by a high proportion
of Basidiomycete DNA (Fig 1, B), which is assigned by QIIME to
unknown Malasezziales. BLAST results for these sequences are
most consistent with M restricta or a closely related species.
Levels of fungus are highly variable between individuals but the
highest levels of fungus are observed in severe asthmatics (see
Fig E2 in this article’s Online Repository at www.jacionline.
org). When fungal loads are higher (>2-fold average) than those
observed in healthy individuals, the increased load is always
due to additional burden of A fumigatus complex (Fig E2). A fu-
migatus complex (Fig 1, B) forms the largest proportion of fungi
in the disease groups.29 ITS1 is not useful for precise assignment
of species within the A fumigatus complex and so assignation ofspecies in this clade is represented as A fumigatus species com-
plex only. Reverse BLAST1 analysis using formatted fastq files
as databases confirmed species identification.Diverse A fumigatus complex sequences are
observed in individual lungs
To further analyze the diversity of A fumigatus complex se-
quences in our samples, all A fumigatus sequences were extracted
from the fastq files and filtered to remove sequences with
Phred scores <30 to minimize any possibility that sequencing er-
rors gave rise to sequence diversity. Typical results are shown as
phylogenetic trees in Fig 2. A core set of identical ITS sequences
representing between 22% and 61% of the total retrieved se-
quences was found in each sample. These identical sequences
sit at the center of the radial cladograms shown. Each diverse
ITS sequence is shown as a branch on the cladogram with phylo-
genetic distance indicated by the scale. For all samples, the
branches consist of only 1 diverse ITS sequence.Comparison of the lung mycobiome by disease and
treatment
The secondary objective in this study was to determinewhether
different therapy could be associated with the mycobiome
composition of the lung. To determine whether particular therapy
or phenotype was associated with altered mycobiome, we
compared groups of individuals in this study by disease and
treatment type. The groups are complex with considerable
potential for confounding treatments or conditions. For example,
many individuals receiving antifungal therapy are also receiving
steroid therapy. We estimated fungal burden using QIIME fungal
composition (Fig 1) adjusted using fungal load as determined by
total fungal RT-PCR, as well as by total fungal RT-PCR alone and
Aspergillus-specific RT-PCR.7
FIG 1. Mycobiome composition of BAL from individuals with allergic disease. A, Level of fungus in BAL as
assessed by total fungal RT-PCR. Cycle threshold values were converted into genome equivalents by cali-
bration against known samples. B, Fungal composition of each sample. The color key for the most common
taxons is given below the diagram. C, Patient information for each sample. Samples are grouped by dis-
ease: ABPA; healthy control subjects; MA, mild asthmatics; SA; SAFS. Antifungal (AF) and steroid treatment
is indicated by the bars above the disease type with key below the diagram.
FIG 2. Variation in the A fumigatus population in individual samples. Two
typical samples are shown for patient 34 (healthy control) and 35 (SA). A
fumigatus-specific sequences were extracted from fastq files by BLAST1,
then aligned using MUSCLE trimmed in ALIVIEW and trees constructed us-
ing PhyML. Typical A fumigatus sensu stricto and A lentulus sequences
were included in the analysis and are indicated in the figure. Each tree
shows a core set ofA fumigatus sequences with 84 of 256 sequences for pa-
tient 34 and 260 of 458 for patient 35 being identical to the A fumigatus
sequence. Trees are constructed using ITS1 sequence to demonstrate
isolate variation, but they are unlikely to represent true speciation.
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had lower loads of fungi in their lung samples, patients were
initially grouped into those derived from individuals currently onitraconazole therapy (current group, n 5 17, including 8 with
ABPA and 9 with SAFS), those who had previously been on
itraconazole therapy (previous group, n 5 10, including 5 with
ABPA, 3 with SAFS, and 2 with SA), and those who had never
been given itraconazole (never group, n 5 31, including 3 with
ABPA, 3 with SAFS, 8 with SA, 7 with mild asthma, and 10 who
were healthy control subjects) (Fig 3). Antifungal therapy con-
sisted of oral itraconazole, dosed to achieve therapeutic levels
as determined by repetitive itraconazole blood measurements.
Results based on RT-PCR were used to determine whether this
finding was robust. Our results show that fungal load is compara-
ble between those currently on therapy and those who have never
been treated. In comparison, loads of fungus in individuals with
fungal disease who had stopped taking antifungal therapy are
higher. The highest burden of fungus is observed in individuals
with a history of itraconazole treatment but who were not on itra-
conazole therapy when sampled (previous group). The lowest
fungal burden was observed in individuals never treated with itra-
conazole (never group).
Individuals in the previous group had higher fungal loads than
individuals in the never group or those currently receiving
antifungal therapy (current group). The difference is significant
for only the previous–current comparison (P 5 .018) with the
other comparisons narrowly failing to reach significance
(P values between .1 and .05). This trend occurs in all groups
and subgroups tested, when potentially confounding factors
such as steroid therapy, disease type, sex, etc, are considered.
For comparison of A fumigatus load, differences between current
and never groups or never and previous groups are not significant
(P 5 .79 and P 5 .059, respectively) but comparison of current
and previous groups is significant (P 5 .03).
Preliminary analysis of QIIME data suggested potential
differences in fungal load between corticosteroid treatment and
FIG 3. Effects of antifungal therapy on fungal load in BAL. Per-individual loads of fungus and A fumigatus
grouped by antifungal treatment status. A, Read count-estimated loads of total fungus grouped by anti-
fungal treatment. B, Read count-estimated loads of A fumigatus complex spp grouped by antifungal treat-
ment: CURRENT, individuals currently receiving antifungal therapy; NEVER, individuals that have never
received antifungal therapy; PREVIOUS, individuals that have previously received antifungal therapy.
*P < .05.
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continuous inhaled corticosteroids (ICS). All SA and SAFS
patients were treated with a combination of ICS and oral
corticosteroid (OCS). Some patients with ABPA received a
combination of continuous ICS plus intermittent OCS therapy.
No mild asthma or normal healthy control subjects received
steroids (OCS or ICS). A significant difference between thera-
peutic groups was observed for corticosteroid treatment (Fig 4, A
and B). We initially observed that individuals with ABPA that
were receiving corticosteroid therapy showed significantly higher
total fungal loads than individuals not receiving corticosteroid
therapy (see Fig E3 in this article’s Online Repository at www.
jacionline.org). The most significant difference between groups
was found when considering antifungal therapy with or without
corticosteroid treatment (Fig 4, C and D). The other variables in
our dataset did not appear to further confound the data analysis.
Fungal burden is slightly lower in individuals receiving antifungal
treatment but not corticosteroid therapy when compared with in-
dividuals who have never received antifungal therapy. However,
fungal burden is significantly higher in individuals receiving
corticosteroid treatment independent of antifungal therapy.DISCUSSION
To our knowledge, this is the first study to identify the
composition of the mycobiome in lungs of individuals with
fungal disease. We show differences in fungal load in groups of
individuals receiving corticosteroid treatment and antifungal
therapy. The lung mycobiome varies substantially between
individuals but is always at low levels in healthy individuals
and increased load is always due to higher levels of A fumigatus
complex.
A fumigatus complex is the predominant fungus in the lungmy-
cobiome in asthma and allergic fungal disease. Individuals
receiving corticosteroid therapy have significantly higher loads
of fungus in their lungs than those not receiving steroid therapyirrespective of their underlying disease. None of the mild asth-
matic or healthy control subjects were on therapies that are pre-
dicted to influence their lung mycobiome or bacterial
microbiome, and so these findings probably reflect the normal
mycobiome of Caucasians in the North West of England.
In general, our study shows comparable levels and taxa of fungi
as were shown in previous studies.33-36 Additionally we manually
removed fungal species identified as arising from reagent contam-
ination. In our study, we did not observeWallemia spp contamina-
tion.37 This study was limited by the numbers of patients that
could feasibly be imaged using bronchoscopy and the high vari-
ability of fungal levels between samples. Therefore statistical po-
wer in some comparisons is low. However, we note that where
specific treatments can be separated from confounding factors,
significant differences in mycobiome associated with treatment
can be observed, even with the limited numbers obtained. Future
studies would benefit from either much larger recruitment of in-
dividuals with fungal disease or by careful selection of individuals
using narrow treatment and/or endotype criteria. Lavage aliquots
from several washes were combined in this study to maximize re-
covery of fungal DNA, and the resulting data are likely to repre-
sent the combined bronchial and bronchoalveolar fungal
communities.
In addition to A fumigatus complex, we found a wide variety of
other fungi. Our analysis shows a higher proportion of Aspergillus
than has been previously reported with lower loads of
Candida.10,37 Control experiments using no sample or spiked
BAL samples from cough patients did not suggest that the effi-
ciency of PCR and sequence assignation from C albicans was
lower than that observed with A fumigatus, indicating that the
observed lower level of Candida spp is not caused by PCR or
sequencing bias. Manual assignment of fungal taxa from the fastq
files suggested that closed-reference organized taxonomic unit
workflows using larger ITS databases, containing manymore rep-
resentatives of closely related fungal species, could be a more ac-
curate reflection of species and fungal burden. ITS1 is not a
FIG 4. Per-individual averaged loads of fungus and A fumigatus grouped by antifungal and corticosteroid
treatment. A, Read count-estimated loads of fungus grouped by corticosteroid treatment. B, Read count-
estimated load of A fumigatus complex spp grouped by corticosteroid treatment. C, Quantitative PCR-
determined loads of fungus grouped by both antifungal treatment and corticosteroid treatment: 1, current
itraconazole treatment with no steroid treatment, 2, current itraconazole treatment with current steroid
treatment; 3, previous itraconazole treatment with current steroid treatment; 4, previous itraconazole treat-
ment with no steroid treatment; 5, no itraconazole treatment with no steroid treatment; and 6, no itracona-
zole treatment with no steroid treatment. D, Quantitative PCR determined loads of A fumigatus grouped by
both antifungal treatment and corticosteroid treatment (groups 1 to 6 as defined in C). All individuals with
previous antifungal therapy have SAFS or ABPA. *P < .05; **P < .01.
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fumigatus complex and therefore precise taxonomic interpreta-
tion of these results is not feasible.29 Our ITS primer set does
not amplify Pneumocystis jirovecii, but P jirovecii is likely to
be present in some individuals.
Fungal burdens in the lungs of individuals with asthma or
severe forms of asthma are comparable to those in individuals
with well-characterized allergic fungal disease. Fungal loads are
highly variable between individuals with very high loads of
fungus occurring only in those with ABPA, mild asthma, and
severe asthma. The difference in fungal load is almost always
caused by increased level of A fumigatus complex fungi. This
might suggest that SAFS is simply a variant form of SA with a
disproportionate IgE sensitivity and associated immunopatho-
logic reactions to fungi. The high variability in fungal load meansthat the differences between disease groups observed are not sig-
nificant. Alpha-diversity metrics do not suggest differences in
composition between these groups.
The observation of diverse sequences in the A fumigatus com-
plex group (Fig 2) suggested that infection or colonization did not
arise from a single inoculum. Assuming that identical ITS1 se-
quences represent expansion of mycelium from a small inoculum,
then the presence of a high proportion of identical ITS sequences
in all samples suggests that a substantial proportion of the A fumi-
gatus complex in any given sample arises from a single inoculum
or a dominant strain. The remaining sequences are diversewith no
sequence duplicated and suggest the presence of a wide range of
fungi from the A fumigatus complex in each diseased persons’
lungs. It is possible that lungs of individuals with excess mucus
(a characteristic feature of asthma) act as efficient spore traps
J ALLERGY CLIN IMMUNOL
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relative loads of fungus observed simply reflect environmental
abundance and the physical dynamics of spore deposition for
small sporing fungi. However, it is well known that there are ge-
netic factors that predispose some individuals to ABPA, and these
factors may also explain why some individuals have higher
fungal burden.38,39 Alternatively, the excess mucus could ‘‘pro-
tect’’ A fumigatus from phagocytic attack or differential adhesion
to epithelial cells.40 In any scenario, at least some of the inhaled
spores probably germinate, forming mycelia that produce aller-
gens in the airways.41 Substantial mycelium is commonly
observed intermingled with eosinophils and neutrophils in plugs
of sputum from asthmatics supporting the hypothesis that at least
some of the fungal population could grow from a single
inoculum.42
Inhaled corticosteroids are commonly administered to asth-
matic patients. We found that individuals receiving corticoste-
roids without antifungal therapy had higher total fungal loads in
the lungs. This result mirrors that seen in chronic obstructive
pulmonary disease patients based on sensitive culture techniques
and high-dose ICS.43 Corticosteroids impair monocyte, macro-
phage, and neutrophil phagocytosis of A fumigatus.44 If the un-
proven assumption that the fungal load of A fumigatus reflects
allergen load is true, then this has important implications for man-
agement of allergy in these individuals. If steroids do increase
fungal burden as our results suggest, then minimizing and moni-
toring of fungal burden may be a useful route for management.
We note, however, that in these patients, the increased fungal
burden observed is not linked to demonstrably worse disease us-
ing the immunological tools we currently have. A fumigatus pro-
duces over 80 IgE-binding proteins,45 so the potential for immune
stimulation in the airways is high. ABPA is generally treated with
steroid therapy with remission of symptoms5; however, relapse is
frequent on discontinuation. The interaction of steroid treatment
with the lung mycobiome in such cases would clarify the effects
of steroid treatment on fungal burden. One potential weakness of
this study is the lack of information regarding cumulative steroid
use in the cohort, if this is important. Increased cumulative use
could be a factor determining fungal burden, and correlation of
cumulative steroid use and fungal burden is a future objective
for this work. A further possibility is that the age of the study par-
ticipants may also determine fungal burden. We are unable to
show any confounding effect for age in our data; however, the
numbers of individuals in the study groups are small, and we
cannot rule out the possibility that age-related effects may emerge
from larger study numbers in the future. One other potential effect
of age may be that it is correlates with increased cumulative ste-
roid exposure.
As expected, individuals receiving antifungal therapy had
lower loads of fungus in the lungs, and it is striking that the
load in individuals who stopped antifungal therapy was signifi-
cantly higher than in untreated individuals. Individuals with
worse asthma linked to fungal allergy in our practice are more
often prescribed antifungal medications, and it is of great interest
that higher fungal loads in their lungs are associated with
cessation of therapy.
The links between increased fungal load and OCSs, or
cessation of antifungal therapy are telling. Steroid therapy for
fungal allergic disease has a long history of successful use;
however, it is possible that overuse of steroids may encourage
fungal growth in the lungs, leading to future recurrence ofsymptoms. A careful sequential analysis of the mycobiome
before, during, and after steroid or antifungal therapy would
shed light on this issue. Increased sample sizes would improve
statistical analysis. Sequential studies following mycobiome
composition and level during the course of treatment would
clarify our observations and frame the debate on the use of
corticosteroids in the therapy of allergic fungal disease.
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Clinical implications: This is the first study assessing lung
fungal populations in fungal disease and to assess mycobiomes
in individuals receiving steroids or antifungal therapy. This in-
formation may influence therapy in fungal allergic disease.REFERENCES
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